Cumulatively, these findings indicate that GAS5 may blunt the resistance of glioma cells to cisplatin by suppressing excessive autophagy through the activation of mTOR signaling, implying a promising therapeutic strategy against chemoresistance in glioma.
Silencing of GSTM3 with GSTM3 siRNA decreased the proliferation, migration and invasion but increased the apoptosis of glioma cell lines U251 and U87, which was similar to that the effect lncRNA GAS5 over-expression.
Compared with the GAS5 ins/ins genotype, the ins/del genotype or the del/del genotype was significantly associated with 1.57-fold or 2.61-fold increased glioma susceptibility (p = 0.001 or p = 9.0 × 10<sup>-6</sup>).